ROBOSENSE
RoboSense LiDAR , the leading Smart LiDAR Sensor provider, boasts 10 percent of the market share worldwide, ranking first in China and second globally, according to the “LiDAR for Automotive and Industrial Applications Report 2021 ” from Yole Développement, an international market research and strategic consultancy. The report covers the market share of automotive and industrial applications of over ten leading LiDAR companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005530/en/
RoboSense has been designated as an official long-term partner for many auto companies, and receiving orders for its RS-LiDAR-M1 (M1), RoboSense’s second-generation solid-state LiDAR, for a diverse range of mass-produced models since July 2020. These orders cover traditional automobile manufacturers and a supercar brand. Among them, GAC-Aion officially announced its plans to equip multiple models with RoboSense LiDAR in July this year .
The report also noted that mechanical LiDAR systems, including rotary and rotating mirror systems, have been losing market share since 2020 due to cost and reliability issues. It goes on to state that second-generation MEMS Smart LiDAR systems are entering the mainstream as its technology matures and cost gets more competitive.
World's first mass-produced automotive-grade solid-state LiDAR
RoboSense’s M1 employs advanced MEMS technologies. Launched in 2016 and with a demo prototype on the way next year, M1 was first shown at the International Consumer Electronics Show (CES) in 2018 and won two CES Innovation Awards in 2019 and 2020.
With over five years of research and dozens of upgrades, M1 became the first product to have a mass-production version finalized. RoboSense began mass-produced automotive-grade production of M1 in Q2 2021, and has since delivered over ten batches for models through its long-term automobile manufacturer partnerships.
Exclusive smart “GAZE” functionalities
M1 boasts an exclusive smart functionality named “GAZE”, which dynamically improves resolution and frame rate based on the environment, enabling vehicles to zoom in and out and augmenting their perception.
M1 enhances central resolution and extends the range of identification from 150 to 200 meters on highways, so that the vehicle can detect distant road conditions earlier. On city roads, M1 increases the frame rate from 10Hz to 20Hz and scans obstacles – such as pedestrians, electric bicycles and traffic jams – at a higher frequency for stronger near-field detection.
A multi-sensor, LiDAR-centric solution is key for accuracy and detection safety, whose reliability is known as the first step towards safe smart mobility. As Chinese LiDAR companies continue making breakthroughs in the global march towards smart mobility, RoboSense has become a leader in China and will continue in its commitment to innovate and supply the global intelligent automotive value chain with LiDAR solutions, accelerating the evolution of smart mobility.
About Yole Développement (www.yole.fr ）
Yole Développement provides market research, technology analysis, strategy consulting, targeted media, and financial advisory services. With a strong focus on emerging applications using silicon and/or micro manufacturing since 1998, Yole Développement has expanded to include more than 80 collaborators worldwide.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005530/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom